You will find 10 complete masterclasses with the latest Advances in Hematology and Hemotherapy, presented by one of the world’s leading experts in this field”

At present, the field of Hematology is pioneering innovation in diagnosis and treatment, and it should be noted that hematologists are leaders in the clinical application of immunotherapy in the fight against the different hematological cancers.  

Various international scientific societies involved with Hematology strive to swiftly incorporate the results of biomedical research into clinical practice, especially the treatment of hematological malignancies (blood cancers), but also iron deficiency and anemias, the administration of direct-acting oral anticoagulants-DOACs, bone marrow transplants and, in the long-term, research focused on obtaining artificial blood, with the ultimate aim of ensuring that these techniques are incorporated into the national healthcare provision as soon as possible. 

In terms of knowledge and technology, Hematology and Hemotherapy is one of the fastest progressing medical disciplines in recent decades, thanks to the integration of biological and clinical findings, leading to a better understanding of disease mechanisms, thereby facilitating the development of more appropriate clinical action guidelines. All of this has contributed to hematology and hemotherapy reaching a remarkable level of prominence and justifying its future as an integrated speciality, with this program representing an ideal framework for building expertise in this area. 

This Professional master’s degree in Advances in Hematology and Hemotherapy comprises a complete teaching program that establishes it as is a high-level scientific course aimed at healthcare professionals who care for patients or populations with blood diseases on a daily basis, incorporating the latest advances in research and sound scientific evidence.  Additionally, this program is supported by a multidisciplinary approach to topics, which allows for learning and professional development in a range of areas.

That is why this 100% online program in Advances in Hematology and Hemotherapy endorses the latest advances in research and the highest scientific evidence. With a solid and educational program, which includes masterclasses given by an international eminence in the area, it is positioned as a teaching product of the highest scientific rigor at international level, aimed at health professionals who in their daily clinical practice deal with the care of patients or populations with hemorrhagic diseases. In addition, the program is supported by a multidisciplinary approach to its subjects, which allows a thorough and professional improvement in different areas.

With the Professional master’s degree in Advances in Hematology and Hemotherapy you will have the opportunity to update your knowledge in a comfortable way and without sacrificing the utmost scientific rigour"

This Professional master’s degree in Advances in Hematology and Hemotherapy contains the most complete and up-to-date scientific program on the market. The most important features include:  

• More than 75 clinical cases presented by hematology experts. Graphic, schematic, and practical contents which provide scientific and practical information on the disciplines that are essential for professional
• Diagnostic-therapeutic developments on assessment, diagnosis, and treatment for hematology patients
• Practical exercises where a self-evaluation process can be carried out to improve learning
• Clinical and diagnostic imaging test iconography
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• A special emphasis on evidence-based medicine and research methodologies in hematology
• All this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Professional master’s degree may be the best investment you can make in the selection of a refresher program for two reasons: in addition to updating your knowledge in Advances in Hematology and Hemotherapy, you will obtain a Professional master’s degree from TECH Global University"

The teaching body is made up of respected and renowned professionals with extensive experience in healthcare, teaching, and research, who have worked in many countries where these diseases are prevalent. 

The methodological design of this Professional master’s degree has been developed by a multidisciplinary team of e-learning experts. It integrates the latest advances in educational technology for the creation of numerous multimedia educational tools that allow the professional to address real problems in their daily clinical practice, based primarily on the problem-based learning method. This will allow them to advance by acquiring knowledge and developing skills that will impact their future professional work. 

This Professional master’s degree is distinguished by the fact that all of the topics, as well as the videos, self-assessments, clinical cases and exams, have been thoroughly reviewed, updated, and integrated by the team of experts that make up the faculty, to ensure that the learning process is orderly and instructive and therefore achieves the program's objectives. 

This program offers instruction in simulated environments, which provides an immersive learning experience designed to prepare professionals for real-life situations"

It includes clinical cases to bring the program's degree as close as possible to the reality medical care"

The teaching program has been created by a group of professors and medical professionals from various disciplines, with extensive medical, research and teaching experience in several countries in Africa, Central and South America, interested in integrating the latest and most up-to-date scientific knowledge in Hematology and Hemotherapy to ensure professional development to improve the daily clinical practice of professionals. 

This Professional master’s degree in Advances in Hematology and Hemotherapy contains the most complete and up-to-date scientific program on the market” 

Module 1. Recent Discoveries in Hematopoiesis, Cytogenetics and Immunophenotyping in Hematology

1.1. Current Role of Hematopoietic Multipotent Cell, Progenitor Cells,Growth Factors, and Cytokines

1.1.1. Hematopoietic Stem Cells: Characteristics and Functions
1.1.2. Progenitor Cells
1.1.3. Hematopoietic Growth Factors
1.1.4. Cytokines

1.2. Biopathology of Granulopoiesis and Monocytopoiesis

1.2.1. Biopathology of Granulopoiesis
1.2.2. Biopathology of Monocytopoiesis

1.3. Advances in the Structure and Function of Lymphoid Tissue

1.3.1. Structure of Lymphoid Tissue
1.3.2. Types of Lymphoid Tissue
1.3.3. Function of Lymphoid Tissue

1.4. Immune System Current Events: Development, Regulation, and Activation of B and T Cells

1.4.1. Development and Regulation of the Innate Immune System
1.4.2. Development and Regulation of the Adaptive Immune System
1.4.3. Immune System Functions
1.4.4. Immunosuppression

1.5. Differentiation Antigens: Latest Findings

1.5.1. Types of Differentiation Antigens
1.5.2. Physiology
1.5.3. Diagnostic Utilities

1.6. New Developments in Megakaryopoiesis and Thrombopoiesis

1.6.1. Biology of Megakaryopoiesis
1.6.2. Biology of Thrombopoiesis

1.7. Cell Cultures and Cytokines Update

1.7.1. Types of Cell Cultures
1.7.2. Cell Culture Biology
1.7.3. Cell Culture Uses
1.7.4. Cytokines and their Role in Cell Differentiation

Module 2. Update on the Importance of Laboratories in Hematology and Hemotherapy

2.1. Development of Specialized Laboratory Techniques in Recent Years

2.1.1. Handling of Autoanalyzers
2.1.2. Cytomorphology of Peripheral Blood
2.1.3. Bone Marrow Cytomorphology: Cytochemical Techniques: Bone Marrow Aspiration, Medulogram

2.2. Anemic Syndrome Diagnostic Techniques: Recent Advances

2.2.1. Hemoglobin and Hematocrit
2.2.2. Peripheral Lamina
2.2.3. Reticulocyte Count
2.2.4. Hemolysis Tests
2.2.5. Other Tests for Studying Anemia

2.3. Flow Cytometry in the Diagnosis of Hematologic Diseases

2.3.1. Fundamentals and Methodology of the Cytometry Technique
2.3.2. Usefulness in the Diagnosis of Hematologic Diseases

2.4. Basic Cytogenetic and Molecular Biology Techniques

2.4.1. Principles of Cytogenetics
2.4.2. Cytogenetics and Genetic Rearrangements in Hematologic Diseases
2.4.3. Cytogenetic Techniques
2.4.4. Principles and Techniques of Molecular Biology in Hematology

2.5. New Techniques of Hemostasis and Thrombosis

2.5.1. Tests that Measure the Functioning of Primary Hemostasis
2.5.2. Tests that Measure the Functioning of Secondary Hemostasis
2.5.3. Evidence of Physiological Inhibitors of Coagulation

2.6. Immunohematology Techniques: Present and Future

2.6.1. Basis and Methodology of Immunohematology Techniques
2.6.2. Usefulness for Diagnosing Hematologic Diseases

2.7. Therapeutic Apheresis Techniques: Current Developments

2.7.1. Plasmapheresis
2.7.2. Leukoapheresis
2.7.3. Erythroapheresis
2.7.4. Thrombocytapheresis

2.8. Current Techniques for the Procurement, Handling and Preservation of Hematopoietic Progenitor Cells 

2.8.1. Progenitor Cell Donor Selection
2.8.2. Progenitor Mobilization in Autologous and Healthy Donor
2.8.3. Apheresis of Hemopoietic Progenitors in Autologous and Allogeneic Transplantation
2.8.4. Bone Marrow Extraction by Surgical Procedure
2.8.5. Lymphocyte Collection: Procedure, Indications, Complications
2.8.6. Product Suitability Tests: Minimum Cellularity, Viability, Microbiological Studies
2.8.7. Progenitor Infusion: Procedure and Complications

Module 3. Update on Anemia 

3.1. Mechanism of Erythropoiesis, Erythroid Differentiation and Maturation

3.1.1. Biopathology and Physiopathology of Erythrocytes
3.1.2. Structure and Types of Hemoglobin
3.1.3. Functions of Hemoglobin

3.2. Classification of Erythrocyte Disorders and Clinical Manifestations

3.2.1. Classification of Erythrocyte Disorders
3.2.2. Symptoms and Signs of Anemia by Organ Systems

3.3. Pure Red Cell Aplasia

3.3.1. Concept
3.3.2. Etiology
3.3.3. Clinical Manifestations
3.3.4. Diagnosis
3.3.5. Current Treatment Alternatives

3.4. Congenital Dyserythropoietic Anemia

3.4.1. Concept
3.4.2. Etiology
3.4.3. Clinical Manifestations
3.4.4. Diagnosis
3.4.5. Current Treatments

3.5. Iron Deficiency Anemia, Iron Metabolism Disorders and Iron Overload: Current Management

3.5.1. Concept
3.5.2. Classification and Etiology
3.5.3. Clinical Picture
3.5.4. Staged Diagnosis of Iron Disorders
3.5.5. Treatment Variants of Iron Disorders

3.6. Megaloblastic Anemia: Recent Advances

3.6.1. Concept
3.6.2. Classification and Etiology
3.6.3. Clinical Picture
3.6.4. Diagnostic Approach
3.6.5. Current Treatment Schemes and Recommendations

3.7. Hemolytic Anemia: From Laboratory to Clinic

3.7.1. Concept
3.7.2. Classification and Etiology
3.7.3. Clinical Picture
3.7.4. Diagnostic Challenges
3.7.5. Alternative Treatments

3.8. Hemoglobin Disorder Anemia

3.8.1. Concept
3.8.2. Classification and Etiology
3.8.3. Clinical Picture
3.8.4. Analytical Diagnostic Challenges
3.8.5. Treatment Variants

Module 4. Scientific Developments in Spinal Cord Disorders  

4.1. Medullary Aplasia

4.1.1. Definition
4.1.2. Epidemiology and Etiology
4.1.3. Clinical Manifestations
4.1.4. Clinical and Staged Diagnosis according to Diagnostic Tests
4.1.5. Latest Treatment Recommendations

4.2. Myelodysplastic Syndromes: Latest Classifications

4.2.1. Definition
4.2.2. Epidemiology
4.2.3. Clinical Manifestations
4.2.4. Diagnosis and Current Classifications
4.2.5. Current Review of the Treatment and Use of Hypomethylating Therapy

4.3. Updated Approach to Agranulocytosis

4.3.1. Definition
4.3.2. Epidemiology and Etiology
4.3.3. Clinical Manifestations
4.3.4. Diagnostic Complexities
4.3.5. New Developments in Treatment

4.4. Polycythemia Vera

4.4.1. Definition
4.4.2. Epidemiology
4.4.3. Clinical Manifestations
4.4.4. Diagnosis
4.4.5. Current Treatment Alternatives

4.5. Essential Thrombocythemia

4.5.1. Definition
4.5.2. Epidemiology
4.5.3. Clinical Manifestations
4.5.4. Diagnosis
4.5.5. Treatment Review

4.6. Chronic Idiopathic Myelofibrosis

4.6.1. Definition
4.6.2. Epidemiology
4.6.3. Clinical Manifestations
4.6.4. Diagnosis
4.6.5. Therapeutic Approaches

4.7. Hypereosinophilic Syndrome

4.7.1. Definition
4.7.2. Epidemiology
4.7.3. Clinical Manifestations
4.7.4. Diagnostic Complexities
4.7.5. Treatment: Literature Review

4.8. Mastocytosis

4.8.1. Definition
4.8.2. Epidemiology
4.8.3. Clinical Manifestations 
4.8.4. Use of Diagnostic Tests
4.8.5. Alternative Treatments

Module 5. Current Events in Hemostasis Physiology 

5.1. Update on the Biopathology of Hemostasis Types

5.1.1. Primary Hemostasis
5.1.2. Secondary Hemostasis

5.2. Advances in Vascular Endothelium Biology and Functions

5.2.1. Vascular Endothelium Biology
5.2.2. Vascular Endothelium Functions
5.2.3. Main Vascular Endothelial Mediators
5.2.4. Endothelial Dysfunction

5.3. Platelets and their Role in Coagulation: Recent Discoveries

5.3.1. Platelet Formation
5.3.2. Platelet Functions and Mediators
5.3.3. Platelets in Hemostasis 

5.4. Plasma Factors and the Coagulation Cascade: From Research to the Clinic

5.4.1. Synthesis and Structure of Coagulation Factors
5.4.2. Functions of Plasma Coagulation Factors in the Coagulation Cascade
5.4.3. Coagulation Factor Deficiency

5.5. Blood Coagulation Cofactors

5.5.1. Vitamin K and Coagulation
5.5.2. Prekallikrein
5.5.3. High Molecular Weight Cininogen
5.5.4. Von Willebrand Factor

5.6. Physiological Inhibitors of Coagulation

5.6.1. Antithrombin
5.6.2. Protein C - Protein S System
5.6.3. Antitrypsins
5.6.4. Antiplasmins
5.6.5. Other Coagulation Inhibitor Proteins

5.7. Current Events in Pregnancy and Hemostasis

5.7.1. Hemostasis Changes during Pregnancy
5.7.2. Fibrinolysis Changes during Pregnancy

5.8. New Developments in Hemostasis in Hepatic Insufficiency and Renal Insufficiency

5.8.1. Acute Hepatic Insufficiency and Hemostatic Disorders
5.8.2. Chronic Hepatic Insufficiency and Hemostatic Disorders
5.8.3. Hemostasis in Chronic Kidney Disease
5.8.4. Hemostasis in Patients with Renal Function Replacement Treatment

Module 6. Update on Coagulation, Thrombosis and Fibrinolysis Tests 

6.1. Primary and Secondary Hemostasis Assessment Tests

6.1.1. Tests to Assess the Role of the Vascular Endothelium
6.1.2. Tests to Assess the Role of Platelets in Hemostasis
6.1.3. Tests that Assess the Role of Coagulation Factors in the Enzymatic Cascade

6.2. Interpretation of Prothrombin, Thrombin and Activated Thromboplastin Times

6.2.1. Prothrombin Time Interpretation
6.2.2. Thrombin Time Interpretation
6.2.3. Interpretation of Activated Thromboplastin Time

6.3. Usefulness of Thromboelastography: Its Current Role

6.3.1. Definition
6.3.2. Use
6.3.3. Interpretation

6.4. Fibrinolysis Tests: The Mediators of Tissue Reperfusion

6.4.1. Tests that Assess Fibrinolysis
6.4.2. Uses
6.4.3. Interpretation

6.5. Diagnosis of Hemophilia: Traditional and the Latest Techniques

6.5.1. Types of Hemophilia
6.5.2. Tests to Diagnose Hemophilia

6.6. Monitoring Coagulation in Patients with Critical Bleeding Disorders

6.6.1. Hemostasis in Critically Ill Patients
6.6.2. Tests for Monitoring Bleeding Disorders in Critically Ill Patients

6.7. Laboratory Monitoring of Patients on Oral Anticoagulants

6.7.1. Traditional and New Oral Anticoagulants
6.7.2. Evidence for Monitoring Patients on Direct Oral Anticoagulants

6.8. Laboratory Monitoring in Patients Treated with Heparins

6.8.1. Heparins in Anticoagulant Treatment
6.8.2. Tests for Monitoring Heparin Treatment

Module 7. New Developments in Major Bleeding Disorders 

7.1. Vascular Bleeding Disorders

7.1.1. Definition
7.1.2. Epidemiology
7.1.3. Clinical Manifestations
7.1.4. Diagnostic Difficulties
7.1.5. Treatment Developments

7.2. Platelet Hemorrhagic Disorders

7.2.1. Definition
7.2.2. Epidemiology and Etiology
7.2.3. Clinical Manifestations
7.2.4. Diagnostic Complexities
7.2.5. New Treatment Approaches

7.3. Hemophilia

7.3.1. Definition
7.3.2. Epidemiology
7.3.3. Clinical Manifestations
7.3.4. Diagnosis
7.3.5. Treatment and Current Issues in Electrical Therapy

7.4. Von Willebrand Disease: Diagnostic and Therapeutic Challenge

7.4.1. Definition
7.4.2. Epidemiology
7.4.3. Clinical Manifestations
7.4.4. Diagnosis by Screening Tests
7.4.5. Treatment

7.5. Bleeding Disorders due to Vitamin K Deficiency

7.5.1. Definition
7.5.2. Epidemiology
7.5.3. Clinical Manifestations
7.5.4. Etiological Diagnosis
7.5.5. Treatment Plans

7.6. Bleeding Disorders due to Excess Anticoagulants

7.6.1. Definition
7.6.2. Epidemiology
7.6.3. Clinical Manifestations
7.6.4. Diagnostic Tests
7.6.5. Treatment Complexities

7.7. Acquired Bleeding Disorders

7.7.1. Definition
7.7.2. Epidemiology
7.7.3. Clinical Manifestations
7.7.4. Diagnosis: The Role of Necessary Tests
7.7.5. Treatment

7.8. Disseminated Intravascular Coagulation: Recent Findings

7.8.1. Definition
7.8.2. Epidemiology and Etiology
7.8.3. Clinical Manifestations
7.8.4. Use of Diagnostic Tests
7.8.5. Alternative Treatments

Module 8. Update on Antihemorrhagics

8.1. Antihemorrhagic Drugs

8.1.1. Definitions
8.1.2. Main Drugs
8.1.3. Mechanism of Action
8.1.4. Main Indications

8.2. Use of Vitamin K in Bleeding Disorders

8.2.1. Indication of Vitamin K in Bleeding Disorders
8.2.2. Pharmacokinetics and Pharmacodynamics
8.2.3. Presentation and Dosage

8.3. Coagulation Factor Concentrate

8.3.1. Therapeutic indications
8.3.2. Pharmacokinetics and Pharmacodynamics
8.3.3. Presentation and Dosage

8.4. Use of Fresh Frozen Plasma and Protamine Sulfate

8.4.1. Therapeutic Indications
8.4.2. Pharmacokinetics and Pharmacodynamics
8.4.3. Presentation and Dosage

8.5. Latest Recommendations for the Use of Platelets

8.5.1. Therapeutic Indications
8.5.2. Pharmacokinetics and Pharmacodynamics
8.5.3. Presentation and Dosage

8.6. Platelet Aggregation Inhibitors: The Reality of Use

8.6.1. Therapeutic Indications
8.6.2. Pharmacokinetics and Pharmacodynamics
8.6.3. Presentation and Dosage

8.7. Capillary Protective and Hemostatic Vasoconstrictor Drugs

8.7.1. Therapeutic Indications
8.7.2. Pharmacokinetics and Pharmacodynamics 
8.7.3. Presentation and Dosage

8.8. Antifibrinolytics

8.8.1. Therapeutic indications
8.8.2. Pharmacokinetics and Pharmacodynamics
8.8.3. Presentation and Dosage

Module 9. Advances in Leukemia, Lymphoma and other Oncohematological Diseases 

9.1. Hodgkin’s Lymphoma

9.1.1. Epidemiology
9.1.2. Typification and Immunophenotyping 
9.1.3. Clinical Manifestations
9.1.4. Diagnosis and Staging 
9.1.5. Current Treatment

9.2. Non-Hodgkin's Lymphoma

9.2.1. Epidemiology
9.2.2. Typification and Immunophenotyping
9.2.3. Clinical Manifestations
9.2.4. Diagnosis and Staging
9.2.5. Current Treatment

9.3. Acute Lymphocytic Leukemia

9.3.1. Epidemiology
9.3.2. Immunophenotype
9.3.3. Clinical Manifestations
9.3.4. Diagnosis
9.3.5. Current Treatment Alternatives

9.4. Acute Nonlymphocytic Leukemia

9.4.1. Epidemiology
9.4.2. Immunophenotype
9.4.3. Clinical Manifestations
9.4.4. Diagnosis
9.4.5. Current Treatment Alternatives

9.5. Chronic Myeloid Leukemia

9.5.1. Epidemiology
9.5.2. Immunophenotype
9.5.3. Clinical Manifestations
9.5.4. Diagnosis
9.5.5. Current Treatment

9.6. Chronic Lymphocytic Leukemia

9.6.1. Epidemiology
9.6.2. Immunophenotype
9.6.3. Clinical Manifestations
9.6.4. Diagnosis
9.6.5. Current Treatment

Module 10. Update on Plasma Cell Dyscrasias 

10.1. Updated Approach to the Management of Multiple Myeloma

10.1.1. Definition
10.1.2. Epidemiology
10.1.3. Clinical Manifestations
10.1.4. Diagnosis and Staging
10.1.5. Review of Treatment and New Paradigms of Autologous Transplantation

10.2. Solitary Plasmacytoma

10.2.1. Definition
10.2.2. Epidemiology
10.2.3. Clinical Manifestations
10.2.4. Diagnosis
10.2.5. Alternative Treatments

10.3. Waldenström's Macroglobulinemia

10.3.1. Definition
10.3.2. Epidemiology
10.3.3. Clinical Manifestations
10.3.4. Diagnosis
10.3.5. New Treatments

10.4. Heavy Chain Disease

10.4.1. Definition
10.4.2. Epidemiology
10.4.3. Clinical Manifestations
10.4.4. Diagnosis
10.4.5. Treatment

10.5. Monoclonal Gammopathy of Uncertain Significance

10.5.1. Definition
10.5.2. Epidemiology
10.5.3. Clinical Manifestations
10.5.4. Diagnosis
10.5.5. New Treatments

10.6. Amyloidosis

10.6.1. Definition
10.6.2. Epidemiology
10.6.3. Clinical Manifestations 
10.6.4. Diagnosis
10.6.5. Current Treatments

Module 11. New Developments in the General Treatment of Hematologic Diseases

11.1. Antineoplastic Agents

11.1.1. Groups
11.1.2. Mechanisms of Action
11.1.3. Pharmacodynamics
11.1.4. Pharmacokinetics
11.1.5. Dose and Presentation
11.1.6. Adverse Effects

11.2. Treatment of Infections in Hematology Patients

11.2.1. Febrile Neutropenic Patients
11.2.2. Most Frequent Infections in Hematology Patients
11.2.3. Most Frequently Used Antibiotic Treatments

11.3. Hematopoietic Progenitor Cell Transplantation

11.3.1. General Concepts
11.3.2. Indications
11.3.3. Results and Impact

11.4. Methods and Indications for Cell Therapy

11.4.1. General Concepts
11.4.2. Types of Cell Therapy
11.4.3. Indications
11.4.4. Results and Impact

11.5. Principles of Gene Therapy

11.5.1. General Concepts
11.5.2. Indications
11.5.3. Results and Future Impact

11.6. Monoclonal Antibodies in Hematological Malignancies

11.6.1. General Principles
11.6.2. Indications
11.6.3. Impact of Use

11.7. Innovative CAR T-Cell Therapy for Hematological Malignancies

11.7.1. General Principles
11.7.2. Indications
11.7.3. Impact of Use

11.8. Palliative Care for Hematology Patients

11.8.1. General Concepts
11.8.2. Treatment of the Main Symptoms in Oncohematology Patients
11.8.3. Palliative Care in the End-Stage Patient and End-of-Life Care

Module 12. Update on Transfusion Medicine and Hematopoietic Cell Transplantation

12.1. Red Blood Cell Immunology

12.1.1. General Concepts
12.1.2. Blood Groups
12.1.3. Allorecognition/Alloresponse in Transfusion

12.2. Immunology of Leukocytes, Platelets and Plasma Components

12.2.1. General Concepts
12.2.2. Leukocyte Immunology
12.2.3. Immunology of Platelets and Plasma Components

12.3. Hemolytic Disease in Fetuses and Newborns

12.3.1. Definition
12.3.2. Epidemiology
12.3.3. Clinical Manifestations
12.3.4. Diagnosis
12.3.5. Treatment

12.4. Collection, Study and Preservation of Blood and Blood Components

12.4.1. Methods of Obtaining Blood and Blood Derivatives
12.4.2. Preservation of Blood and Blood Derivatives
12.4.3. Care During Transport

12.5. Indications, Efficacy and Complications of Transfusion of Blood, Blood Components and Blood Derivatives

12.5.1. General Principles
12.5.2. Indications
12.5.3. Contraindications
12.5.4. Complications

12.6. Autotransfusion

12.6.1. General Principles
12.6.2. Indications
12.6.3. Contraindications
12.6.4. Complications

12.7. Cell and Plasma Apheresis

12.7.1. General Principles
12.7.2. Types of Apheresis
12.7.3. Indications
12.7.4. Contraindications

This training will be instrumental in advancing your career"